GlassScriptPhysician profile
Rawda Nourain
NPI 1275195570
$1,660.30
in general payments reported to CMS, 2019-2025
14 companies · $1,660 in 2025
The $1,660 reported for 2025 was more than what 89% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2025: $1,660.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,660.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,660.30 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Axsome Therapeutics, INC. | $335.67 | 2025 | Auvelity |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $224.32 | 2025 | Caplyta |
| Neurocrine Biosciences, INC. | $208.95 | 2025 | |
| E.R. Squibb & Sons, L.L.C. | $191.07 | 2025 | Cobenfy |
| Otsuka America Pharmaceutical, INC. | $166.09 | 2025 | Rexulti, Abilify Asimtufii, Abilify Maintena |
| Abbvie INC. | $151.84 | 2025 | |
| Vanda Pharmaceuticals INC. | $135.34 | 2025 | Fanapt |
| Teva Pharmaceuticals USA, INC. | $67.59 | 2025 | Austedo Xr, Uzedy |
| Almatica Pharma LLC | $55.34 | 2025 | Loreev Xr |
| Supernus Pharmaceuticals, INC. | $34.12 | 2025 | Qelbree |
| Corium, LLC | $27.80 | 2025 | Azstarys |
| Harmony Biosciences LLC | $24.39 | 2025 | |
| Alkermes, INC. | $21.46 | 2025 | Lybalvi |
| Janssen Pharmaceuticals, INC | $16.32 | 2025 | Invega Sustenna |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rawda Nourain listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.